Viriom to Present Results of Pre-Clinical Pharmacokinetic Studies with Elsulfavirine and VM1500A Long Acting Injectable Formulations at the International AIDS Society (IAS) Conference 2017
SAN DIEGO, May 22, 2017 /PRNewswire/ -- Viriom Inc. today announced that the data from pre-clinical studies of Elsulfavirine/VM1500A Long Acting Injectable Formulations will be presented at the 9th IAS (International AIDS Society) Conference on HIV Science (IAS 2017), to be held July 23-26 in Paris, France. The studies evaluate new options for the treatment and prevention of HIV/AIDS that would allow for infrequent dosing, thus facilitating patients' adherence, and likely improving long-term treatment outcomes. The results will be presented by Dr. Vadim Bichko, Viriom's Chief Scientific Officer, during a poster viewing session on Wednesday, July 26, 12:30-14:30.
About Viriom
Viriom focuses on treatment, prophylaxis, and eradication of infectious diseases globally. Viriom is developing and commercializing the most innovative, yet affordable solutions to radically broaden global access to antiviral treatments.
Viriom's broad pipeline includes its most advanced drug Elpida®/Elsulfavirine, a once-daily oral prodrug of VM-1500A, a novel HIV non-nucleoside reverse transcriptase inhibitor (NNRTI). Viriom expects to obtain first market registration for Elpida in 2017. Development is underway for once-weekly oral and longer-acting parenteral formulations as well as drug combination formulations. Learn more at http://viriom.com/
Safe Harbor Statement
This document may contain forward-looking statements. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to publicly communicate future expectations. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, the uncertainties associated with product development, the market for our products, the risks associated with dependence upon key personnel and the need for additional financing. We do not assume any obligation to update forward-looking statements as circumstances change. The information in this document is not targeted at the residents of any particular country or jurisdiction and is not intended for distribution to, or use by, any person in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. The future expectations, estimations, anticipated events, results, milestones, events, operating and financial information contained in the company's financial projections and all other areas of this document are for illustrative purposes only and are based upon hypothetical assumptions and events over which the company has only partial or no control. All information about future events (projections) were developed by the company's management and are based upon a variety of assumptions with or without benefit of an operating history. The projections are included solely to provide information concerning the company's estimates of future operating results based on these assumptions and, although the company believes that these assumptions are reasonable, they may be incomplete or incorrect, and unanticipated events and circumstances may occur. Actual results will vary from the projections, and these variations may be material and adverse. The projections should be read in conjunction with the assumptions upon which the projections are based. No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from our projections or the assumptions underlying them.
Media Contact
Ronald Demuth
CFO, Viriom
+1(858)-794-4860x321
[email protected]
SOURCE Viriom Inc.
Share this article